Molbio Diagnostics IPO Day 1 Subscription Reaches 0.34 Times as QIBs Lead Investor Demand
5paisa कैपिटल लिमिटेड
- 2 मिनट में पढ़ें
अंतिम अपडेट: 10 अगस्त 2026 - 04:29 pm
Molbio Diagnostics Limited's initial public offering (IPO) was subscribed 0.34 times by 5:24 PM on August 10, 2026. The public issue received bids for 27,37,620 shares against 81,58,529 shares available for subscription. The Qualified Institutional Buyers (QIBs) category led the demand with a subscription of 0.63 times, followed by the Employee (EMP) portion at 0.46 times, while the Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) portions were subscribed 0.24 times and 0.21 times, respectively.
भारतीय मार्केट में इन्वेस्ट करें और 5paisa के साथ भविष्य की क्षमता को अनलॉक करें!Subscription Status of Molbio Diagnostics IPO
| तिथि | क़िब | एनआईआई | खुदरा | एम्प | कुल |
|---|---|---|---|---|---|
| दिन 1 (अगस्त 10) | 0.63 | 0.24 | 0.21 | 0.46 | 0.34 |
Here are the subscription details for Molbio Diagnostics IPO Day 2, as of 5:24 PM:
| निवेशक की कैटेगरी | सब्सक्रिप्शन (बार) | ऑफर किए गए शेयर | शेयर बिड के लिए | कुल |
|---|---|---|---|---|
| एंकर | 1 | 34,87,717 | 34,87,717 | 281.459 |
| क़िब | 0.63 | 23,25,146 | 14,60,952 | 117.899 |
| एनआईआई | 0.24 | 17,43,859 | 4,15,764 | 33.552 |
| खुदरा | 0.21 | 40,69,004 | 8,51,364 | 343.641 |
| एम्प | 0.46 | 20,520 | 9,540 | 0.770 |
| कुल | 0.34 | 81,58,529 |
27,37,620 |
820.244 |
मुख्य विशेषताएं - दिन 1
- Overall subscription stood at 0.34 times on Day 1 (August 10, 2026).
- Qualified Institutional Buyers (QIBs) subscribed 0.63 times.
- Non-Institutional Investors (NIIs) subscribed 0.24 times.
- रिटेल इन्वेस्टर 0.21 बार सब्सक्राइब कर चुके हैं.
- Employee (EMP) portion subscribed 0.46 times.
- Anchor investors had fully subscribed their allocated portion before the issue opened, with 34,87,717 shares allotted.
- Overall, the IPO was subscribed 0.34 times on the opening day.
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
- मुफ्त IPO एप्लीकेशन
- आसानी से अप्लाई करें
- IPO के लिए प्री-अप्लाई करें
- UPI बिड तुरंत
5paisa पर ट्रेंडिंग
5paisa कैपिटल लिमिटेड
डिस्क्लेमर: सिक्योरिटीज़ मार्केट में इन्वेस्टमेंट मार्केट जोखिमों के अधीन है, इन्वेस्ट करने से पहले सभी संबंधित डॉक्यूमेंट को ध्यान से पढ़ें. विस्तृत डिस्क्लेमर के लिए, कृपया यहां क्लिक करें.